Japan CRO Fuji Biomedix Applies For Bankruptcy Protection
This article was originally published in PharmAsia News
Tokyo-based contract research organization Fuji Biomedix applied for bankruptcy protection Oct. 14. The company has a debt of ¥21.8 billion. In 2006, the company entered purchased several companies. However, the rapid expansion also resulted in a ¥15 billion loan from 21 banks. This September, the company found its profit dropping and lacked the ability to get new loans. The biggest shareholder of the company, Toho Yakuhin, has agreed to take over Fuji's pharmacy business Fuji Family Pharmacy and its 81 drug stores. Japanese CRO Association President Katsuo Nakamura commented that the bankruptcy application will not affect the strong growth of CRO business in Japan. (Click here for more - Japanese language
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.